现有市场上干细胞治疗制品

botizhou

Stem cell therapeutic products on the market
& z  i. a7 w8 p2 z5 Y: q1 T* _& `Updated on Mar. 6, 2012* {  i$ j7 [; |$ F

6 K3 ?- [* s1 K& kInclusion criteria:
* t! t+ F) U# ?% |: a0 n•        Stem cell therapeutic product (drug) was defined as it claimed by a company or regulatory agency. 2 v: D- ?" v$ E% s  F0 w7 A
•        The product is authorized for sales and available on the market. + j8 R& c# e) E; }. p  x2 ?' [
•        The product is approved and/or regulated by federal agency. * @2 K. o( t# O9 @: a8 d0 R* ^

0 f$ }/ }2 c% Q1 K, q' I6 x6 |/ HThe list:
# x' [7 x# A4 S5 F4 M& x: N8 X1. ReliNethra
% i6 ^, |6 R1 wBrand: Reliance Life Science
( K: Y; J5 K' {7 d& k8 RCountry: India
9 r% M2 q: R  q- m3 U  QYear or release: 20086 F7 s, i9 m' A2 |$ [
Regulation: unknown5 k) V: b2 s0 U8 E" o6 T) Z* b
Condition: eye diseases" q5 o2 r- W  G% r
Cell type: limbal stem cells
! |( d7 F  f$ e( X6 _. ADonor type: autologous
) ?2 R0 U+ V3 X1 S6 s, o7 ?2. CardioRel, }7 \2 ?, `0 F
Brand: Reliance Life Science
1 Z( T/ m3 j2 d1 I) @Country: India
$ l5 H7 L# c+ E4 n' X" DYear or release: 2010( @  y8 i; s1 _8 V! D5 g
Regulation: unknown! Y9 Z5 f9 q  w7 L* I9 R
Condition: post acute myocardial infarction
% L- N$ A0 ^  m( A  _- O  }/ OCell type: BM MNC/ MSC- H% B$ j/ m4 W! u  b  a
Donor type: autologous% Q/ C+ \8 _) N. m7 ~
3. Trinity Evolution
$ {. f% V* m3 s, s( uBrand: Orthofix
) F, _7 X$ j& `5 t/ i7 dCountry: USA
( |: D! t$ u) r" N7 ~& c% |Regulation: FDA (HTC/P, 21 CFR, part 1271)+ Q2 |6 N4 [, k- M
Condition: orthopedics' {9 b3 l+ N9 o
Cell type: bone matrix with MSC7 c$ c9 H" t" U$ M
Donor type: allogeneic4 j2 [, S" O6 f, O  X/ @2 F4 F
4. Osteocel Plus
% a7 A" w8 x, K! A4 G* zBrand: NuVasive
. F: P2 g( A7 YCountry: USA
( B5 I$ j( f, d, A  D' H( E/ mRegulation: FDA (HTC/P, 21 CFR, part 1271)/ k( ]8 R; D6 D' S
Condition: orthopedics
8 l1 w" F6 m, R: r3 p5 Y. ^Cell type: BM MSC
# S6 E3 ?; d( M9 q( i1 |Donor type: allogeneic
5 O$ J6 X. U5 n/ Y8 e' h- N5. HeartiCellGram-AMI6 ?' Y% G7 f* o& N2 q2 p
Brand: FCB PharmiCell
9 Q; }- @& q5 h9 v$ tCountry: S. Korea
; u( O  n$ {" N# T3 B! Y: J: hRegulation: KFDA approved
; G% p9 k; {0 h6 L$ S3 VCondition: post acute myocardial infarction
8 J8 W% t+ k" CCell type: BM MSC
0 t4 {& J! _% r" g. xDonor type: autologous# r2 e* Q' A- H: E% d" a: p# s

9 q& z1 b8 H" }4 \! r" g6 h! u$ @( t  ?$ H8 Y
6. Cartistem1 s* u, n, ]. S8 H4 p
Brand: Medipost& R% ?5 T, X) ?' A( g3 z9 _
Country: S. Korea
, I* e! h# s. W! F- }Regulation: KFDA approved6 `% I; d  D7 h9 v9 \" F5 d
Condition: degenerative arthritis* G! n7 K, W4 X4 Q6 n/ y
Cell type: Umbilical cord MSC
' r. N: s: R7 \Donor type: allogeneic1 }( z8 Y9 S- U4 }! ?
7. Cupistem
- E3 T* h. L$ G9 d  t- q1 N, JBrand: Anterogen
% L& Z5 [. o' D+ ^* hCountry: S. Korea8 e6 K2 F$ N+ T6 ^9 h- ~( ]8 a5 s* C6 Y
Regulation: KFDA approved% k8 B* h* j( X' i
Condition: anal fistula (Chron’s disease)* X) ?' j7 R* y
Cell type: Adipose MSC0 f/ j2 \2 r. l* M" ^$ |6 ^
Donor type: autologous% \  X% @, D* P0 p/ B9 k
8. AlloStem
* l: |2 a8 K9 l8 |Brand: AlloSource# ~- I. @1 {, R1 U" |  k
Country: US
2 V3 s% V* l) |+ p) I1 GRegulation: FDA (HTC/P, 21 CFR, part 1271)
+ R! t+ q2 t1 W. W& FCondition: orthopedics
! n9 w/ r( k& _# C3 d& rCell type: Bone matrix + BM MSC5 Q) d' J# M; q. c; G
Donor type: allogeneic
* |9 m) }0 r+ f; K& L" e& U  [" f$ B5 \8 Q& A
Abbreviations: FDA – Food and Drug Administration, KFDA – Korean FDA, MSC – mesenchymal stromal cells, BM – bone marrow, MNC – mononuclear cells.$ F& R+ I8 b  l4 l